Correction (DOI:10.1016/j.jaci.2008.05.029);HIV/AIDS: Waiting for a cure

Journal of Allergy and Clinical Immunology

Volumn 122, Issue 1, 2008, Pages 34-35

  Shearer, William T ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DRUG EFFICACY; DRUG RESEARCH; EDITORIAL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; PRIORITY JOURNAL;

EID: 46049107129     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2008.07.001     Document Type: Erratum

References (18)

1. Moir S., and Fauci A.S. Pathogenic mechanisms of B-lymphocyte dysfunction in HIV disease. J Allergy Clin Immunol 122 (2008) 12-19
2. Haynes B.F., and Shattock R.J. Critical issues in mucosal immunity for HIV-1 vaccine development. J Allergy Clin Immunol 122 (2008) 3-9
3. Sekaly R.P. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?. J Exp Med 205 (2008) 7-12
4. von Bubnoff A. The 15th Annual Meeting had its share of sobering news from clinical trials, but researchers also reported many exciting advances. IAVI Rep 12 (2008) 1-5
5. Cohen J. AIDS research. Did Merck's failed HIV vaccine cause harm?. Science 318 (2007) 1048-1049
6. Steinbrook R. One step forward, two steps back-will there ever be an AIDS vaccine?. N Engl J Med 357 (2007) 2653-2655
7. Cohen J. Retrovirus meeting. Back-to-basics push as HIV prevention struggles. Science 319 (2008) 888
8. Brown D. Vaccine failure is setback in AIDS fights: test subjects may have been put at risk of contracting AIDS (March 21, 2008), Washington Post A1
9. Rethinking is urged on a vaccine for AIDS. New York Times (March 26, 2008) A13
10. Kaiser J. AIDS research. Review of vaccine failure prompts a return to basics. Science 320 (2008) 30-31
11. Shen L., and Siciliano R.F. Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection. J Allergy Clin Immunol 122 (2008) 22-28
12. Singh K.K., Lieser A., Ruan P.K., Fenton T., and Spector S.A. An age-dependent association of mannose-binding lectin-2 genetic variants on HIV-1-related disease in children. J Allergy Clin Immunol 122 (2008) 173-180
13. Ji X., Gewurz H., and Spear G.T. Mannose binding lectin (MBL) and HIV. Mol Immunol 42 (2005) 145-152
14. Spear G.T., Zariffard M.R., Xin J., and Saifuddin M. Inhibition of DC-SIGN-mediated trans infection of T cells by mannose-binding lectin. Immunology 110 (2003) 80-85
15. Foster S.B., McIntosh K., Thompson B., Lu M., Yin Y., Rich K.C., et al. Increased incidence of asthma in HIV-infected children treated with highly active antiretroviral therapy in the National Institutes of Health Women and Infants Transmission Study. J Allergy Clin Immunol 122 (2008) 159-165
16. Reveille J.D., and Williams F.M. Infection and musculoskeletal conditions: rheumatologic complications of HIV infection. Best Pract Res Clin Rheumatol 20 (2006) 1159-1179
17. Foster S.B., Lu M., Thompson B., MacDonald K.S., Winchester R.J., Rich K.C., et al. HLA inheritance and asthma in HIV-infected children. Clin Immunol 127 Suppl (2008) S46
18. bright activated T cells. J Allergy Clin Immunol 122 (2008) 166-172